Evaluation of antimicrobial susceptibilities of non-tuberculous mycobacteria against linezolid and tigecycline

Şenol, Güneş; Biçmen, Can; Gunduz, Ayriz; Dereli, Şevket; Erbaycu, Ahmet Emin

doi:10.1016/j.ijmmb.2022.03.012

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite not being recommended by guidelines linezolid is used as alternative treatment for MAC, M. kansasii , M. xenopi and is one of the preferred drugs for RGMs including macrolide-susceptible and resistant Mabs strains [ 20 ]. The Mycobacterium isolation and resistance test is important before the initiation of linezolid for NTM treatment considering that they have different resistance rates according to the species; the majority of Mabs clinical isolates showed susceptibility to linezolid, while less than 20% of MAC clinical isolates were susceptible to linezolid [ 141 , 142 ].…”

Section: Antimicrobials Used For Treating Ntm-associated Infectionsmentioning

confidence: 99%

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

Calcagno,

Coppola,

Sarmati

et al. 2024

Infection

View full text Add to dashboard Cite

Background Non-tuberculous mycobacteria (NTM) are generally free-living organism, widely distributed in the environment, with sporadic potential to infect. In recent years, there has been a significant increase in the global incidence of NTM-related disease, spanning across all continents and an increased mortality after the diagnosis has been reported. The decisions on whether to treat or not and which drugs to use are complex and require a multidisciplinary approach as well as patients’ involvement in the decision process. Methods and Results This review aims at describing the drugs used for treating NTM-associated diseases emphasizing the efficacy, tolerability, optimization strategies as well as possible drugs that might be used in case of intolerance or resistance. We also reviewed data on newer compounds highlighting the lack of randomised clinical trials for many drugs but also encouraging preliminary data for others. We also focused on non-pharmacological interventions that need to be adopted during care of individuals with NTM-associated diseases Conclusions Despite insufficient efficacy and poor tolerability this review emphasizes the improvement in patients’ care and the needs for future studies in the field of anti-NTM treatments.

show abstract

Section: Antimicrobials Used For Treating Ntm-associated Infectionsmentioning

confidence: 99%

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

Calcagno,

Coppola,

Sarmati

et al. 2024

Infection

View full text Add to dashboard Cite

show abstract

Evaluation of antimicrobial susceptibilities of non-tuberculous mycobacteria against linezolid and tigecycline

Cited by 1 publication

References 23 publications

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

Contact Info

Product

Resources

About